Home / News / Hatchtech completes $12.5M capital raise, secures funds for phase III trial and NDA submissions, and announces board changes

Hatchtech completes $12.5M capital raise, secures funds for phase III trial and NDA submissions, and announces board changes

31 October 2013

Posted in — Media Release

Share

Learn More

Share

You may also like

02 August 2020

FDA Approves Xeglyze™ for the topical treatment of head lice infestation

Media Release

02 August 2020

Hatchtech gets lice treatment nod from FDA

News, The Australian Financial Review

01 February 2018

No nit picking: Head lice group Hatchtech gets green light to trials

News, The Australian Financial Review

21 October 2014

Hatchtech announces successful results from Phase 2 ovicidal study

Media Release

View All

Ventured. Gained.

Subscribe to our Newsletter.

Name
decor
decor decor decor
decor decor decor decor decor